British Journal of Clinical Pharmacology

Drug therapy in kidney disease
pp. 509-511(3)
Author: Aronson, Jeffrey K

Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers
pp. 512-526(15)
Authors: Mant, Timothy G. K.; Bradford, Daniel; Amin, Dipti M.; Pisupati, Jaya; Kambayashi, Yoshikazu; Yano, Yoshitaka; Tanaka, Kazushige; Yamada-Sawada, Takuko

Pharmacokinetics of a novel agent, R667, in patients with emphysema
pp. 527-533(7)
Authors: Chiu, Yu-Yuan; Roth, Michael D; Kolis, Stanley; Rogovitz, David; Davies, Brian

Pharmacokinetics of desloratadine in children between 2 and 11 years of age
pp. 534-540(7)
Authors: Gupta, Samir; Khalilieh, Sauzanne; Kantesaria, Bhavna; Banfield, Christopher

Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients
pp. 541-547(7)
Authors: Naesens, Maarten; Verbeke, Kristin; Vanrenterghem, Yves; Kuypers, Dirk

A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab
pp. 548-561(14)
Authors: Hayashi, Naoto; Tsukamoto, Yuko; Sallas, William M.; Lowe, Philip J.

Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers
pp. 562-574(13)
Authors: van Doorn, Martijn; Vogels, Jack; Tas, Albert; van Hoogdalem, Ewoud Jan; Burggraaf, Jacobus; Cohen, Adam; van der Greef, Jan

The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension
pp. 575-582(8)
Authors: Lefebvre, Jean; Poirier, Luc; Poirier, Paul; Turgeon, Jacques; Lacourciere, Yves

Assessment of renal function in clinical practice at the bedside of burn patients
pp. 583-594(12)
Authors: Conil, J. M.; Georges, B.; Fourcade, O.; Seguin, T.; Lavit, M.; Samii, K.; Houin, G.; Tack, I.; Saivin, S.

Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials
pp. 595-613(19)
Authors: Gomeni, Roberto; Merlo-Pich, Emilio

Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects
pp. 614-617(4)
Authors: Zhao, Qian; Jiang, Ji; Li, XiaoMing; Lu, Zhihong (Sarah); Hu, Pei

Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist
pp. 618-622(5)
Authors: Gerskowitch, V. P.; Hodge, J.; Hull, R. A. D.; Shankley, N. P.; Kalindjian, S. B.; McEwen, J.; Black, J. W.

Quality of requests for serum digoxin concentrations: experience from an Australian Regional Health Service
pp. 623-627(5)
Authors: Ellington, Chris; Grgurinovich, Nick; Miners, John O.; Mangoni, Arduino A.

Palatability of angiotensin II antagonists among nephropathic children
pp. 628-631(4)
Authors: Meier, Chiara M.; Simonetti, Giacomo D.; Ghiglia, Silvia; Fossali, Emilio; Salice, Patrizia; Limoni, Costanzo; Bianchetti, Mario G.

Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment
pp. 632-632(1)
Author: Fenske, Martin

Authors' response: Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment
pp. 633-633(1)
Authors: Chen, Ya-Chi; Nafziger, Anne N.; Bertino, Joseph S.; Kashuba, Angela D. M.

Reverse transcriptase inhibitors in HIV/AIDS therapy
pp. 634-634(1)

Erratum
pp. 635-635(1)